A BRAF new world.

Frisone D; Friedlaender A; Malapelle U; Banna G; Addeo A

doi:10.1016/j.critrevonc.2020.103008

Back

Journal article

A BRAF new world.

Frisone D IOSI - Oncology Institute of Southern Switzerland, Switzerland.
Friedlaender A Department of Oncology, Geneva University Hospital, Switzerland.
Malapelle U Department of Public Health, University Federico II of Naples (Naples), Italy.
Banna G Department of Oncology, United Lincolnshire Hospital Trust, UK.
Addeo A Department of Oncology, Geneva University Hospital, Switzerland. Electronic address: Alfredo.addeo@hcuge.ch.

2020-06-03

Published in:

Critical reviews in oncology/hematology. - 2020

Carcinoma, Non-Small-Cell Lung

English BRAF is a rare targetable mutation in non-small-cell lung cancer (NSCLC). Emerging evidence underlines that, rather than a single point mutation, BRAF genes present with a wide array of mutations, essentially in lung adenocarcinoma. Different BRAF mutations have divergent clinical and therapeutic implications, with a particular distinction between V600E and non-V600E mutations. The latter are at least as frequent in NSCLC as V600E, but lack any proven targeted therapy. In this paper, we briefly review the current literature and provide an update of scientific knowledge about different types of BRAF mutations in NSCLC.

Language